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Abstract
We investigated the prevalence of extended-spectrum b-lacta-
mases (ESBLs) in Enterobacter spp. bloodstream isolates from 19
hospital laboratories in Norway during 2011. A total of 62/230
(27%) isolates were resistant to third-generation cephalosporins
and four (1.7%) were ESBL-positive; blaCTX-M-15 (n = 3) and
blaSHV-12 (n = 1). This is comparable to the prevalence of ESBLs in
clinical isolates of Escherichia coli and Klebsiella pneumoniae in
Norway during the same period. All ESBL-positive isolates were
multidrug resistant (MDR) and harboured plasmid-mediated
quinolone resistance. Three isolates supported transfer of large
IncHI2-plasmids harbouring ESBL- and MDR-encoding genes to
E. coli recipients by in vitro conjugation.
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In several studies the prevalence of extended-spectrum
b-lactamases (ESBLs) in clinical Enterobacter spp. isolates has
been comparable to, or higher than, among Escherichia coli and
Klebsiella spp. [1,2]. As in E. coli and Klebsiella spp., CTX-M and
SHV-type b-lactamases have been the predominant ESBLs in
Enterobacter spp. [1–4].
Detection of ESBLs in Enterobacter spp. is complicated by
the chromosomally encoded AmpC b-lactamase, which con-
ceals ESBL production in many phenotypical assays. Synergy
testing using clavulanic acid and fourth-generation cephalo-
sporins (e.g. cefepime) is an accurate strategy to overcome this
problem [1]. Detection of ESBLs in Enterobacter spp. has been
considered by some to be of limited clinical value, because
cephalosporins are seen as inappropriate treatment of infec-
tions caused by these species. In contradiction to this, several
studies have reported outbreaks of ESBL-producing Enterob-
acter species in health-care facilities [2,5–7]. It is plausible that
Enterobacter spp. may act as a reservoir of ESBL-containing
plasmids for other Enterobacteriaceae [1,2,7,8]. Plasmids
harbouring ESBL-encoding genes often confer resistance to
other antibiotic classes, limiting treatment options.
Further, a study from Korea comparing the clinical outcome
of bloodstream infections caused by ESBL-producing and
non-ESBL-producing Enterobacter spp. showed a signiﬁcantly
increased length of hospital stay after bacteraemia episodes
among patients with ESBL-producing isolates [3].
In this study we investigated the prevalence of ESBL
production among Enterobacter spp. bloodstream isolates from
Norway, as well as the potential for transfer by conjugation of
ESBL-containing plasmids from Enterobacter spp. to E. coli.
During 2011, 230 consecutive, non-repetitive Enterobacter
spp. bloodstream isolates were collected from 19 Norwegian
hospital laboratories. Identiﬁcation and susceptibility testing
were performed using Vitek 2 (bioMerieux, Marcy l’Etoile,
France). Isolates with an MIC >1 mg/L for cefotaxime and/or
ceftazidime were further investigated. Stuart et al. found these
criteria to have 100% sensitivity for detection of ESBLs in
Enterobacter spp. (personal communication). Sixty-two isolates
met the selection criteria, their identiﬁcation was conﬁrmed by
Matrix Assisted Laser Desorption/Ionization Time-of-Flight
mass spectrometry (MALDI-TOF MS) using the MALDI
BIOTYPER 3.0 software (Bruker Daltonics, Bremen, Germany).
Extended phenotypical susceptibility testing was performed
using gradient MIC strips (Lioﬁlchem, Roseto degli Abbruzzi,
Italy) containing cefepime, cefotaxime, ceftazidime, cefoxitin,
meropenem, ciproﬂoxacin, gentamicin and trimethoprim–sul-
phamethoxazole. Synergy testing with cefepime and clavulanic
acid was performed using MIC strips as well as combination
tablets (Rosco, Taastrup, Denmark). Molecular detection of
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blaSHV, blaTEM and blaCTX-M was performed according to
previously published methods [9,10]. Isolates concomitantly
resistant to third-generation cephalosporins and with a
ciproﬂoxacin MIC ≥0.125 mg/L were examined for the pres-
ence of plasmid-mediated quinolone resistance determinants
using PCRs targeting aac(6′)-Ib/aac(6′)-Ib-cr, qnrS, qnrA, qnrB
and qnrC [11,12]. Plasmid characterization of ESBL-producing
isolates was performed by in vitro conjugation into E. coli
recipients J53-1 and J53-2, as well as PCR-based replicon typing
[13]. In addition, plasmid proﬁling was performed by pulsed-
ﬁeld gel electrophoresis (PFGE) separation of S1-nuclease
digested total DNA and Southern blot hybridization [14]. The
ESBL-producing isolates were investigated for genetic related-
ness by XbaI-PFGE using the Tenover criteria for interpreta-
tion [14,15].
Using MALDI-TOF MS, the 62 isolates resistant to
third-generation cephalosporins were identiﬁed as Enterobacter
aerogenes (n = 9) and Enterobacter cloacae complex (n = 53),
including Enterobacter asburiae (n = 6), Enterobacter hormaechei
(n = 3) and Enterobacter ludwigii (n = 1). Four of the 230
isolates (1.7%) were identiﬁed as ESBL-producers. All were
Enterobacter cloacae, originating from three geographically
distinct hospitals. XbaI-PFGE showed them to be different
pulsotypes with at least seven band differences between strains
(data not shown). Three isolates harboured blaCTX-M-15 and
one isolate harboured blaSHV-12. In addition, all ESBL-positive
isolates harboured blaTEM-1. With respect to plasmid-mediated
quinolone-resistance determinants, all ESBL isolates were
positive for qnrB and the isolates with blaCTX-M-15 were also
positive for aac(6′)-Ib-cr. The blaSHV-12 isolate was positive for
aac(6′)-Ib. In addition, a single ESBL-negative isolate was also
positive for both qnrB and aac(6′)-Ib-cr. The four ESBL-
producing Enterobacter cloacae were the only isolates displaying
a multidrug-resistance proﬁle as deﬁned by resistance to
quinolones, aminoglycosides and trimethoprim–sulphameth-
oxazole. The cefepime + clavulanic acid combination strip and
the combination tablets showed the following test properties
for detection of ESBL-production: sensitivity 100%/100%,
speciﬁcity 98%/95%, positive predictive value 80%/57%, and
negative predictive value 100%/100%, respectively.
Conjugal transfer of ESBL genes to E. coli recipients was
achieved from two CTX-M-15-positive isolates and from the
blaSHV-12 isolate. QnrB and aac(6′)-Ib-cr/aac(6′)-Ib were
co-transferred along with the ESBLs. The three donors and
their transconjugants were positive for IncHI2 by PCR-based
replicon typing. PFGE of S1 nuclease-digested total DNA and
subsequent Southern blot hybridization with blaCTX-M-15 and
IncHI2 probes showed that blaCTX-M-15 was located on large
transferable IncHI2-type plasmids of approximately 300 kb
(data not shown). In the blaSHV-12 transconjugant only one
300 kb plasmid was observed, indicating that blaSHV-12 was also
located on a large IncHI2 plasmid. The plasmid transfer
frequency to E. coli was calculated as 10–5 per donor cell on
average.
A similar study from the Netherlands during 2006–07 found
an ESBL prevalence in Enterobacter spp. of 14% [1]. This was
almost twice their local ESBL-prevalence among E. coli and
K. pneumoniae from the same period. In our study the
prevalence of ESBL production among Enterobacter spp.
bloodstream infections was comparable to E. coli and K. pneu-
moniae in surveillance data from the same time period [16].
The observed similarity in size and rep-type of ESBL-containing
plasmids among Norwegian Enterobacter spp. isolates of
different pulsotypes, and from geographically distinct sites,
support in vivo dissemination of plasmids. The successful in vitro
conjugation to E. coli recipients is also of concern and supports
the notion that plasmid exchanges can occur in vivo between
Enterobacter spp. and other Enterobacteriaceae. This is also
supported by other reports, which have found Inc HI2
plasmids of similar size in both Enterobacter spp., Klebsiella
spp. and E. coli. In addition to their broad host range, the
Inc HI2 plasmids seem able to harbour a variety of genes
encoding resistance to both b-lactams, quinolones and amino-
glycosides [17,18].
We conclude that detection of ESBL-production among
Enterobacter spp. is important. This can easily be achieved in
the routine laboratory by synergy testing using fourth-
generation cephalosporins and clavulanic acid for isolates
displaying resistance to third-generation cephalosporins.
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